BRVE vs URGN: stock comparison and AI forecast
Braveheart Bio, Inc. (BRVE) and Urogen Pharma Ltd. (URGN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BRVE Braveheart Bio, Inc.
- Price
- $21.51 -26.9% · 6M
- Market Cap
- $1.76B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
- NO CURRENT FORECAST
URGN Urogen Pharma Ltd.
- Price
- $34.36 +47.5% · 6M
- Market Cap
- $1.68B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- BRVE and URGN have similar market capitalizations ($1.76B and $1.68B).
- Over the last six months URGN returned +47.5% and BRVE -26.9%.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BRVE | URGN |
|---|---|---|
| Market Cap | $1.76B | $1.68B |
| Revenue/Share | – | $3.86 |
| FCF/Share | – | $-3.26 |
Profitability & Margins
| Metric | BRVE | URGN |
|---|---|---|
| ROA | – | -38.6% |
| ROIC | – | -35.0% |
| Gross Margin | – | 91.8% |
| Operating Margin | – | -35.3% |
| Net Margin | – | -51.7% |
| EBT Margin | – | -52.0% |
| Tax Rate | – | 0.5% |
Financial Health
| Metric | BRVE | URGN |
|---|---|---|
| Current Ratio | 13.63x | 3.80x |
| Quick Ratio | – | 3.41x |
| Interest Coverage | – | -18.7x |
| Working Capital | $114M | $174M |
Cash Flow
| Metric | BRVE | URGN |
|---|---|---|
| Operating Cash Flow | – | -$159M |
| Free Cash Flow | – | -$159M |
| Capital Spending | – | -$220K |
| FCF/Sales | – | -84.3% |
| CapEx/Sales | – | 0.1% |
Operational Efficiency
| Metric | BRVE | URGN |
|---|---|---|
| Asset Turnover | – | 0.75x |
| Receivables Turnover | – | 2.1x |
| Inventory Turnover | – | 0.6x |
| Fixed Assets Turnover | – | 316.1x |
| Days Sales Outstanding | – | 172 days |
| Days Inventory | – | 580 days |
| Payables Period | – | 365 days |
| Cash Conversion Cycle | – | 387 days |
Income Statement
| Metric | BRVE | URGN |
|---|---|---|
| Total Revenue | – | $189M |
| Operating Income | – | -$67M |
| Net Income | – | -$98M |
| R&D Expense | – | $61M |
| SG&A Expense | – | $177M |
| Cost of Goods Sold | – | $15M |
Dividend & Shareholder Information
| Metric | BRVE | URGN |
|---|---|---|
| Shares Outstanding | 82M | 49M |
BRVE vs URGN: stock comparison and AI forecast
Which is bigger, BRVE or URGN?
BRVE and URGN have similar market capitalizations ($1.76B and $1.68B).
Which stock performed better over the last six months, BRVE or URGN?
Over the last six months URGN returned +47.5% and BRVE -26.9%.
Which one does Intratio's AI model rank higher, BRVE or URGN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.